Press releases
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
- Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
- Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
- Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
More ▼
Key statistics
As of last trade Akeso Inc (4RY:MUN) traded at 3.80, 3.26% above its 52-week low of 3.68, set on Aug 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.80 |
---|---|
High | 3.80 |
Low | 3.80 |
Bid | 3.74 |
Offer | 3.84 |
Previous close | 4.12 |
Average volume | 0.00 |
---|---|
Shares outstanding | 865.86m |
Free float | 634.96m |
P/E (TTM) | 13.55 |
Market cap | 30.65bn HKD |
EPS (TTM) | 2.61 HKD |
Data delayed at least 15 minutes, as of May 29 2024 07:13 BST.
More ▼